Abstract
Th1 cell-mediated immune responses at the site of active infection are important to restrict the growth of M.tuberculosis (MTB) and for the spontaneous resolution of patients with tuberculous pleurisy (TBP). In the present study, we found that without any stimulation, CD4+ T cells in pleural fluid cells (PFCs) from patients with TBP expressed significantly higher levels of CD69 than PBMCs from patients with tuberculosis (TB) or healthy donors. CD4+CD69+ T cells expressed T-bet and IL-12Rβ2. After stimulation with MTB-specific antigens, CD4+CD69+ T cells expressed significantly higher levels of IFN-γ, IL-2 and TNF-α than CD4+CD69− T cells, demonstrating that CD4+CD69+ T cells were MTB-specific Th1 cells. In addition, CD4+CD69+ T cells were mostly polyfunctional Th1 cells that simultaneously produced IFN-γ, IL-2, TNF-α and displayed an effector or effector memory phenotype (CD45RA−CCR7−CD62L−CD27−). Moreover, the percentages of CD4+CD69+ T cells were significantly and positively correlated with polyfunctional T cells. Interestingly, sorted CD4+CD69+ but not CD4+CD69− fractions by flow cytometry produced IFN-γ, IL-2 and TNF-α that were significantly regulated by CD4+CD25+ Treg cells. Taken together, based on the expression of CD69, we found a direct quantitative and qualitative method to detect and evaluate the in vivo generated MTB-specific polyfunctional CD4+ T cells in PFCs from patients with TBP. This method can be used for the potential diagnosis and enrichment or isolation of MTB-specific Th1 cells in the investigations.
Introduction
Tuberculous pleurisy (TBP) is characterized by an intense chronic accumulation of inflammatory cells at the disease site, including the activation of Th1 cells and their preferential recruitment to the affected areas [1], [2]. However, TBP remains difficult to identify despite numerous diagnostic tools [3]. Currently, the definite diagnosis of tuberculosis (TB) pleural effusions depends on the demonstration of acid-fast bacilli in the sputum, pleural fluid, or pleural biopsy specimens [4]. Moreover, high levels of IFN-γ are detected in tuberculosis pleural fluid [5], [6]. Therefore, measurement of IFN-γ in the pleural fluid has also gained wide acceptance in the diagnosis of TB pleural effusions [7]. However, these assays did not provide information regarding antigen-responsive cells. An abundance of immunocompetent cells in the pleural effusion provides investigators with a good model to study the correlates of a protective immune response at the site of infection. The enrichment of Th1 cells in pleural fluid has been previously documented [8]. However, detailed phenotypic and functional characterizations for these cells are still unknown.
The BCG vaccine is an attenuated strain of Mycobacterium bovis and includes loss of the esx 1 locus, which encodes two family members, culture filtrate protein of 10 kDa (CFP-10) and early secretory antigenic target 6 (ESAT-6). These antigens have an important diagnostic role in distinguishing BCG vaccination from MTB infection [9]–[13]. Although ESAT-6 and CFP-10 contain numerous potential T cell epitopes, the immune response during infection is often focused toward a few immunodominant epitopes. In the present study, we selected the six most dominant peptides identified in ESAT-6 and CFP-10, as reported to be frequently recognized by subjects in Indian, European, Cambodian, and Middle Eastern cohorts with both latent and active TB [14]–[19].
It has already been demonstrated that T-lymphocytes in the lungs, both in normal individuals and in those with granulomatous disease, are almost entirely CD45RO+ memory T cells and express both early- and late-activation markers, such as CD69 and CD29 respectively [20]. Previous data have demonstrated that almost all of the CCR5+ and CCR3+CD4+ T cells recruited to the lungs of patients with active TB express the memory T-cell phenotype and that the majority may have been recently activated [21]. CD69 is a membrane molecule transiently expressed on activated lymphocytes, and its selective expression in inflammatory infiltrates probably suggests that it plays a role in the pathogenesis of inflammatory diseases [22]. Previous studies have also demonstrated the usefulness of the determination of CD69 on CD4+ T cells after in vitro stimulation with tuberculin as a rapid indicator of immune sensitization against MTB [23], [24]. However, these studies did not directly assess the function of CD69+ cells.
The present study was initially designed to analyze the discrepancy of phenotypes among pleural fluid cells (PFCs) from patients with TBP, PBMCs from TB patients and normal donors. We found a significant increase in CD69 expression on CD4+ T cells in PFCs. Importantly, CD4+CD69+ cells were mostly Th1 cells specific for ESAT-6 and CFP-10 peptides. The phenotypic and functional analysis of CD69-expressing cells strongly suggested that CD69 could be a useful marker for the identification or enrichment of antigen specific Th1 cells at local sites following MTB infection. CD69 may be useful for diagnostic procedures, including specific immune monitoring during TB infection or after vaccination, as well as for therapeutic applications such as targeted adoptive Th1 cell therapies.
Results
Significantly higher expression of CD69 on CD4+ T cells in PFCs from patients with TBP than in PBMCs from TB patients and healthy donors without any stimulation
Our initial experiments assessed the surface expression of CD69 on CD4+ T cells from PFCs of patients with TBP and PBMCs from TB patients (PTB) and healthy donors (HD). As expected, without any stimulation, a significantly higher level of CD69 expression was observed on CD4+ T cells from PFCs of TBP patients than on PBMCs from either PTB or HD (Fig. 1A and B, P<0.001). Moreover, higher levels of CD69 expression (11.60%±11.93%, mean ± SD) on CD4+ T cells were observed in 78% of the PFCs from individuals with TBP than on the PBMCs of PTB or HD (1.48%±1.60% for healthy donors and 1.38%±1.68% for TB patients, mean ± SD). No significant difference in CD69 expression was observed on PBMCs from PTB and from HD (Fig 1B, P = ns). In addition, we also demonstrated that CD4+CD69+ T cells expressed significantly higher levels of HLA-DR than CD4+CD69− T cells, a molecule which is usually induced on CD4+ T cells after activation (Fig 1C and D, P<0.001). Unexpectedly, no significant difference was observed in the expression of CD25, another activation marker, which is usually temporally expressed on activated T cells or constitutively expressed on regulatory T cells (Fig 1C and D, P = ns).
Significantly higher expression of T-bet and IL-12Rβ2 by CD4+CD69+ T cells than by CD4+CD69− T cells
In order to confirm whether CD4+CD69+ T cells in PFCs were Th1 cells, we further evaluated the expression of T-bet, an important transcription factor specific for Th1 cells. The results showed that more than 90% of CD4+CD69+ T cells and about 57.24% of CD4+CD69− T cells expressed T-bet (Fig 2A). The expression of T-bet on CD4+CD69+ T cells was significantly higher than that on CD4+CD69− T cells (Fig 2B, P<0.01). We next examined the expression of IL-12Rβ2, another marker highly specific for differentiated Th1 cells. Similar to the results obtained for T-bet expression, the majority of CD4+CD69+ T cells constitutively expressed IL-12Rβ2 (Fig. 2A), and the expression was significantly higher than that observed on CD4+CD69− T cells (Fig 2C, P<0.05 ), further confirming that the CD4+CD69+ T cell subset was highly enriched for Th1 cells.
ESAT-6 and CFP-10 peptides-specific Th1 cells were preferentially enriched within CD4+CD69+ T cells
Because CD4+CD69+ T cells were predominantly Th1 cells, we aimed to examine whether direct ex vivo evaluation of surface expression of CD69 without in vitro upregulation permits direct assessment of MTB-specific Th1 cells. Our initial experiments indicated that stimulation of PFCs with ESAT-6 and CFP-10 peptides resulted in increased surface CD69 expression that is difficult to elucidate (Data not shown). Short-term stimulation of these cells includes incubation with secretion inhibitory brefeldin A (BFA), which can block the transport of newly synthesized CD69 molecules to the cell surface and thus allows for the direct assessment of the relationship between in vivo CD69 expression and cytokine production. After culturing PFCs with ESAT-6/CFP-10 peptides and BFA, we analyzed the production of Th1 cytokines by intracellular cytokine staining and polychromatic flow cytometry. As shown in Fig 3A and B, CD4+CD69+ T cells produced greater amounts of IFN-γ, IL-2 and TNF-α than did CD4+CD69− T cells. Statistical results demonstrated that the percentages of IFN-γ, IL-2 or TNF-α-producing CD4+CD69+ T cells were significantly higher than those for CD4+CD69− T cells (P<0.001, Fig 3C). In order to further confirm that the responses of T cells were specific for MTB, we also stimulated PFCs from tuberculous pleurisy patients with other irrelevant antigens such as SARS-CoV S peptides (STFFSTFKCYGVSATKL) and (NFSQILPDPLKPTK RSFI) as well as hepatitis B virus surface antigen (HBsAg). We found that these irrelevant antigens could not induce the production of IFN-γ, IL-2 and TNF-α by neither CD4+CD69+ nor CD4+CD69− T cells. However, following stimulation with MTB-specific peptides of ESAT-6/CFP-10, CD4+CD69+ T cells from the same patients expressed high levels of IFN-γ, IL-2 and TNF-α (data not shown).
Significant positive correlation between the percentages of CD69-expressing CD4+ T cells and polyfunctional T cells
It has been suggested that T cells simultaneously producing IFN-γ, IL-2 and TNF-α are associated with protective immunity and concomitant beneficial outcomes, at least in chronic viral infections such as HIV. We therefore compared the expression of IFN-γ, IL-2 and TNF-α in CD4+CD69+, CD4+CD69− and total CD4+ T cells after short-term in vitro stimulation with ESAT-6/CFP-10 peptides. We showed that CD4+CD69+ and CD4+CD69− T cells concurrently and individually produced IFN-γ, IL-2 and TNF-α (Fig 4A, B). This assay also identified cells that expressed CD69 but lacked expression of any cytokine measured (as evidenced by a subset of CD4+CD69+IFN-γ−IL-2−TNF-α− cells). These cells probably contained other effector functions, for example, the secretion of MIP-1β or other cytokines. The total antigen-specific responses were defined as the percentages of T cells expressing any combination of IFN-γ, IL-2 or TNF-α, and thus, seven distinct functional populations could be delineated (IFN-γ/IL-2/TNF-α triple expressers; IFN-γ/IL-2, IFN-γ/TNF-α or TNF-α/IL-2 double expressers; or IFN-γ, IL-2 or TNF-α single expressers). Interestingly, polyfunctional T cells (IFN-γ/IL-2/TNF-α triple expressers) dominated the CD4+CD69+ T cell response. However, frequencies of T cells producing only TNF-α were the highest when analyzing the distribution of the seven subsets within either the CD4+CD69− population or all CD4+ T cells (Fig 4C, D). The percentages of double expressers were similar within CD4+CD69+, CD4+CD69− and total CD4+ T cells. Our results demonstrated that total MTB-specific CD4+ T cells were not dominated by polyfunctional T cells. However, polyfunctional T cells were primarily enriched within CD4+CD69+ T cells. We further analyzed the correlation between the percentages of CD69-expressing CD4+ T cells and polyfunctional T cells. Interestingly, significant positive correlation between CD4+CD69+ T cells and polyfunctional T cells was observed (Fig 4E, p = 0.0003).
CD4+CD69+ T cells were mostly effector memory T cells
We next investigated the phenotype of CD4+CD69+ T cells relating to naïve/memory markers. As shown in Fig 5A, CD4+CD69+ T cells were predominantly CD45RO+CD45RA−, thereby exhibiting a memory cell phenotype. In contrast, CD4+CD69− T cells contained significantly higher percentages of CD45RA+ and lower percentages of CD45RO+ cells than did CD4+CD69+ T cells. Moreover, we also examined the expression of CD127 and CD27 and found that CD4+CD69+ T cells had significantly lower expression of both markers (Fig 5B). To further validate whether MTB-specific CD4+CD69+ T cells were memory cells, we tested the phenotype of IFN-γ-secreting CD4+CD69+ T cells by assessing typical memory T cell markers. As expected, the majority of CD4+CD69+IFN-γ+ T cells displayed a CD45RA−CCR7−CD62L−CD27− effector memory cell phenotype (Fig 5C), suggesting that these cells were capable of producing multiple cytokines quickly at local sites.
CD69 expression identified viable MTB-specific Th1 cells
We further investigated whether purified CD4+CD69+ T cells, stained by fluorescently labeled monoclonal antibody and sorted by flow cytometry, would be compatible with assays that required live cells. We first purified CD4+ T cells and CD14+ cells by positive selection with microbeads. Thereafter, CD4+CD69+ and CD4+CD69− T cell fractions were obtained by flow cytometry-based cell sorting (Fig 6A). We then cocultured CD4+CD69+ or CD4+CD69− T cells with CD14+ cells (as antigen-presenting cells) in the presence of ESAT-6/CFP-10 peptides (P1–P6) and measured the production of Th1 cytokines. Notably, considerable levels of IFN-γ and IL-2 were produced by CD4+CD69+ T cells, whereas little was observed from the CD4+CD69− fractions. However, TNF-α production was readily detected in unstimulated cells, and significantly higher TNF-α was measured following stimulation of the CD4+CD69+ fractions (Fig 6B). Moreover, significantly higher levels of IFN-γ, IL-2 and TNF-α were produced by CD4+CD69+ cells than by CD4+CD69− T cells (P<0.001, Fig 6B). We also assessed percentages of Th1 cytokine-producing cells by flow cytometry. As expected, CD4+CD69+ T cells were highly enriched for IFN-γ, IL-2 and TNF-α production compared with CD4+CD69− cells (Fig 6C–E). Thus, CD69 expression provides a means to identify the vast majority of antigen-specific CD4+ T cells, regardless of the type of cytokine measured. Importantly, our assay conditions based on the CD69 coculture assay retained the ability of cells to secrete multiple cytokines.
CD4+CD25+ T cells inhibit production of Th1 cytokines by CD4+CD69+ T cells
In order to examine whether CD4+CD25+ Treg cells could directly inhibit cytokine production by CD4+CD69+ T cells, we sorted CD4+CD69+ and CD4+CD25+ T cells by flow cytometry (Fig 7A). In order to further confirm that CD4+CD25+ T cells were regulatory T cells, we found that the majority of CD4+CD25+ T cells (>95%) expressed Foxp3(Data not shown), the specific marker for this subset. We further confirmed this observation by incubation of sorted CD4+CD69+ or CD4+CD25+ T cells with CD14+ T cells, respectively. The result demonstrated that neither IFN-γ nor TNF-α was produced by the CD4+CD25+ T cells, whereas CD4+CD69+ T cells produced large amounts of IFN-γ and TNF-α upon coculture (Fig 7B), confirming that CD4+CD25+ T cells were hyporesponsive and represented regulatory T cells. We then cocultured CD4+CD69+ with CD4+CD25+ T cells at different ratios in the presence of CD14+ cells. CD4+CD69+ cells stimulated with ESAT-6/CFP-10 peptides (P1–P6) produced considerably greater amounts of Th1 cytokines compared with unstimulated cells. The addition of CD4+CD25+ T cells into cultures resulted in the inhibition of IFN-γ, IL-2 and TNF-α production in a dose-dependent manner (Fig 7C–E). Overall, our assay conditions showed that CD4+CD25+ cells could inhibit Th1 cytokine production by CD4+CD69+ T cells.
Discussion
Without treatment, tuberculous pleurisy (TBP) usually resolves spontaneously [25] and thus is thought to be a useful model to study the correlates of protective immune responses at the site of infection[26], [27]. Meanwhile, the diagnosis of TBP is difficult and continues to pose clinical challenges. Currently, the two major advances in the diagnosis of TBP have been pleural biopsies[4] and adenosine deaminase (ADA) assessment in pleural fluid [28], [29]. The free (unstimulated) pleural fluid IFN-γ assay is another method established for the diagnosis of TBP[30]. However, both ADA and IFN-γ are non-specific markers of inflammation[30].
The detection of T cell responses specific for defined antigens is essential for the evaluation of pathogenic or protective immunity induced by infectious pathogens or vaccines. CD4+ T cell responses are commonly determined by the expression of various cytokines, such as IFN-γ, IL-2 and TNF-α for Th1 cells, after short-term stimulation with specific antigens. The development of IFN-γ release assays (IGRAs) has emerged as an attractive alternative to the tuberculin skin test for detection of latent TB infections and might also contribute to assisting in the diagnosis of TBP [31]. IGRAs are based on the principle that T cells of individuals sensitized with TB antigens produce IFN-γ when they re-encounter highly MTB-specific antigens such as ESAT-6 and CFP-10. However, this assay precludes further analysis because it is lethal to cells. Moreover, the IGRAs are not recommended on either the blood or the pleural fluid for the diagnosis of TBP [31].
Consistent with other studies, we found that the expression of CD69 was significantly increased on CD4+ T cells in PFCs from patients with TBP [32]. We further demonstrated that the majority of CD4+CD69+ cells were Th1 cells by analyzing expression of the Th1 markers T-bet and IL-12Rβ2. In order to further confirm that CD4+CD69+ cells were mostly MTB-specific T cells, we performed intracellular cytokine staining. We noted that stimulation of PFCs resulted in increased surface CD69 expression. We overcame this limitation by incubation with BFA during short-term stimulation. Using this method, we were able to directly assess the relationship between in vivo CD69 expression and cytokine production. Using polychromatic flow cytometry, we demonstrated for the first time that the majority of MTB specific Th1 cytokine-producing cells were enriched within the CD4+CD69+ subset, whereas CD4+CD69− cells scarcely produced cytokines. In addition, PFCs from tuberculous pleurisy patients were stimulated with SARS-CoV S peptides (STFFSTFKCYGVSATKL) and (NFSQILPDPLKPTKRSFI) as well as hepatitis B virus surface antigen (HBsAg). These irrelevant antigens could not induce the production of IFN-γ, IL-2 and TNF-α by neither CD4+CD69+ nor CD4+CD69− T cells. However, following stimulation with MTB-specific peptides of ESAT-6/CFP-10, CD4+CD69+ T cells from the same patients with tuberculous pleurisy expressed high levels of IFN-γ, IL-2 and TNF-α, indicating that the response was MTB-specific. Most importantly, the detection of CD69 is useful for the direct identification of MTB-specific Th1 cells in vivo without further stimulation.
T cells that produce multiple factors simultaneously are termed polyfunctional T cells and have been shown to provide vaccine-induced immunity and protection against disease progression in HIV-1 infection[33], [34]. In the present study, analysis of total CD4+ Th1 subpopulations indicated that the majority of Th1 cells produced only one cytokine. However, polyfunctional CD4+ T cells simultaneously producing IFN-γ, IL-2 and TNF-α dominated the CD4+CD69+ T cell population, but the percentage of TNF-α single expressers was higher in both the CD4+CD69− and the total CD4+ T cell subsets compared with CD4+CD69− cells. Our results indicated that detection or isolation of CD69+ T cells is a good method for the identification or enrichment of polyfunctional T cells. Interestingly, significant positive correlation was observed between the percentages of CD69-expressing CD4+ T cells and polyfunctional T cells. Our results demonstrated for the first time that the expression of CD69 may be a useful marker for the definition of MTB-specific polyfunctional T cells in vivo. A number of studies in humans suggested that polyfunctional T cells may indeed be involved in mediating protection in TB[34]–[39]. However, it has also been indicated in the recent studies that polyfunctional CD4+ T cells may be a useful biomarker of active TB and that polyfunctional responses are not associated with protection against TB[40]. In the present study, we hypothesized that the highly increased frequencies of CD69-expressing CD4+ T cells (polyfunctional T cells) in pleural fluid may be associated with protection against TB and thus lead to the self-resolution tendency of TBP.
A previous study has indicated that CD4+CD69+CD25− cells represented a new subset of regulatory T cells in the tumor model [41]. These CD4+CD69+CD25− cells are hyporesponsive and can suppress proliferation of CD4+ T cells in a cell-to-cell contact manner. In our study, however, CD4+CD69+ T cells represented effector or effector memory cells and quickly produced large amounts of cytokines following short-term stimulation. Moreover, we also assessed other markers (Foxp3 and CTLA-4) essential for the suppressive function of regulatory T cells and found that these molecules were not differentially expressed by CD4+CD69+ and CD4+CD69− T cells, further confirming that CD4+CD69+ T cells were not regulatory T cells (data not shown). These differing results were probably associated with discrepancies in local circumstances, including cytokines, chemokines and antigen presenting cells that differ between tumor and inflammation contexts. Moreover, it remains to be determined if CD69 is induced by the pleural fluid environment or if CD4+CD69+ T cells are selectively recruited from the circulation.
Previous studies have indicated that CD4+CD25+ T cells can inhibit antigen-specific T cell responses in TB patients[42]–[47]. However, none of these studies has isolated MTB-specific CD4+ T cells directly. In the present study, we purified viable CD4+CD69+ and CD4+CD25+ Treg cells directly and found that CD4+CD25+ Treg cells could inhibit cytokine production by CD4+CD69+ T cells. In addition, our results clearly demonstrated that CD4+CD25+ T cells were hyporesponsive and scarcely produced cytokines following short-term stimulation, further confirming that these cells were regulatory cells. In our previous studies, we have demonstrated that the suppressive effect of Treg cells on IFN-γ production by CD4+CD25+ T cells[43] and γδ T cells[48] was mainly mediated via the release of IL-10 but not TGF-β.
In summary, we demonstrated that CD69 as a useful marker for MTB-specific Th1 cells in PFCs from patients with TBP enabled a direct ex vivo estimation of the quantity, as well as the quality, of MTB-specific Th1 responses. The majority of CD4+CD69+ T cells but not total CD4+ T cells, were dominated by polyfunctional T cells. Importantly, significantly positive correlation was observed between CD69-expressing CD4+ T cells and polyfunctional T cells, suggesting that CD69 is a good marker for the identification or enrichment of polyfunctional T cells in PFCs. Moreover, isolation of live MTB-specific Th1 cells according to surface CD69 expression without any stimulation offers an opportunity for further investigation.
Methods
Ethics Statement
Written informed consent was obtained from all patients and healthy donors. Ethics approval for the present study was obtained from the ethics committee of the Zhongshan School of Medicine, Sun Yat-sen University (Guangzhou, China) and the Chest Hospital of Guangzhou (Guangzhou, China).
Study participants
A total of fifty patients with tuberculous pleurisy (15 females and 35 males, range 18–71 years of age) were recruited from the Chest Hospital of Guangzhou, China. Diagnosis of pleural effusion from TB etiology was based on one of the following criteria: (i) demonstration of MTB on pleural fluid smear (by the Ziehl-Neelsen method); (ii) pleural fluid or pleural biopsy specimens growing M. tuberculosis on Lowenstein-Jensen medium; or (iii) histological evidence of caseating granuloma on biopsy specimens of pleural tissue with positive staining for M. tuberculosis. Twenty-one patients (10 females and 11 males, range 20 to 50 years of age) with active pulmonary tuberculosis (culture-confirmed pulmonary TB) were also included in this study. Patients who had been previously diagnosed with HIV, HBV, or HCV or with a history of autoimmune diseases were excluded from the study. None of the patients was receiving MTB-related treatments at the time of the study. Twenty-two healthy volunteers between the ages of 20 and 54 were recruited from Sun Yat-sen University.
Peptides, reagents and mAbs
For the detection of MTB-specific immune responses, we selected six highly immunogenic and largely HLA-DR-restricted peptides. Four peptides were derived from ESAT-6, and two were derived from the CFP-10 protein of MTB. Synthetic peptides of 20 amino acids (aa) in length were obtained from Shenzhen Hanyu manufacture, Shenzhen, China. The sequences of the peptides are as follows: P1, ESAT-61–20 (MTEQQWNFAGIEAAASAIQG); P2, ESAT-631–50 (EGKQSLTKLAAAWGGSGSEA); P3, ESAT-661–80 (TATELNNALQNLARTISEAG); P4, ESAT-671–90 (NLARTISEAGQAMASTEGNV); P5, CFP-1051–70 (AQAAVVRFQ EAANKQKQELD) and P6, CFP-1071–90 (EISTNIRQAGVQYSRADEEQ). Freeze-dried BCG (Chengdu Institute of Biological Products, Chengdu, China) was reconstituted in a 0.9% sodium chloride solution to a concentration of 1 mg/mL prior to use. Purified anti-CD28 (clone CD28.2) and anti-CD49d (clone 9F10) mAbs were purchased from BD Biosciences (San Jose, CA). The following mAbs were used for phenotypic and intracellular cytokine analysis and were purchased from BD Biosciences (San Jose, CA, USA): CD62L-PE (Dreg56), CCR7-PE (3D12), TNF-α-PE (Mab11), CD69-PE (FN50), T-bet-PE (O4-46), Streptavidin-PE, CD45RA-FITC (L48), CD25-FITC (M-A251), CD4-PerCP (L200), CD8-Pecy7 (RPA-T8), CD69-Pecy7 (FN50), APC-IL-2 (MQ1-17H12), purified rat anti-human CD212 (2B6/12β2), and isotype-matched control antibodies. CD27-APC (O323) was obtained from Biolegend (San Diego, CA). IFN-γ-FITC (45.15) was purchased from Beckman Coulter (Fullerton, CA). Biotin-SP-conjugated affinipure F(ab')2 fragment donkey anti-rat IgG (H+L) was purchased from JacksonImmunoResearch laboratories, Inc. (West Grove, PA).
Preparation of PFCs and PBMCs
PFCs were isolated by lysing erythrocytes using ammonium chloride solution and resuspended to a final concentration of 2×106 cells/mL in complete RPMI 1640 medium (Invitrogen, Grand Island, NY) supplemented with 10% heat-inactivated fetal calf serum (FCS; HyClone, Logan, UT), 100 U/mL penicillin, 100 µg/mL streptomycin, 2 mM L-glutamine, and 50 µM 2-mercaptoethanol. Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Hypaque gradient centrifugation of heparinized venous blood obtained from healthy individuals or TB patients.
Flow cytometry
For the detection of intracellular cytokines, cells were incubated at a concentration of 2×106 cells/mL with 1 µg/mL peptides plus 1 µg/mL anti-CD28 and 1 µg/mL anti-CD49d for 8 h in the presence of brefeldin A (BFA, 10 µg/mL; Sigma-Aldrich, St Louis, MO). For the detection of T-bet, surface markers were first stained and cells were then fixed in 2% formaldehyde, permeabilized in 90% methanol and labeled with anti T-bet mAb. The expression of IL-12Rβ2 was detected by indirect immunofluorescence analysis. Briefly, cells were incubated with mAb for IL-12Rβ2, followed by biotin-SP-conjugated anti-rat IgG F(ab')2 fragments, and were finally incubated with streptavidin-PE. All incubations were performed at 4°C and cells were washed twice between incubations. Flow cytometry was performed using BD FACSCalibur (BD Biosciences) or FACSAria II (BD Biosciences) and the data were analyzed using FlowJo software (TreeStar, San Carlos, CA).
Isolation of cell subsets
CD4+ and CD14+ cells were isolated from PFCs by positive selection with anti-CD4 or anti-CD14 microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany). For isolation of CD4+CD69+, CD4+CD69− and CD4+CD25+ cells, purified CD4+ T cells were stained with PE-conjugated CD69 and FITC-conjugated anti-CD25 and then sorted on a FACSAria II high-speed cell sorter. The purity of cells, as assessed by flow cytometry, was 95–97% for each cell subset.
Cell culture conditions
Purified CD4+CD69+, CD4+CD69− or CD4+ T cells were co-cultured with purified CD14+ cells (at ratio of 1∶2 ) in the presence or absence of BCG, ESAT-6 and CFP-10 peptides. After 48 hours, cell-free supernatants were collected and assessed for IFN-γ, IL-2 and TNF-α production by ELISA kits (BD Bioscience Pharmingen). For the detection of intracellular cytokines, cells were cultured for 8 hours and then subjected to flow cytometry analysis. To examine the role of CD4+CD25+ cells in the regulation of cytokine production by sorted CD4+CD69+ T cells, purified CD4+CD69+ (Teff), CD14+ cells and CD4+CD25+ cells (Treg) were co-cultured in various ratios (Teff:Treg) in the presence of ESAT-6 and CFP-10 peptides. Cell-free supernatants were collected and assessed for IFN-γ, IL-2 and TNF-α by ELISA.
Statistical analysis
The Wilcoxon matched pairs test (Two-tailed) was performed to determine statistical differences between the groups using GraphPad Prism software version 5. Inhibition of cytokine production by CD4+CD25+ T cells was analyzed using the paired Student's t test. A value of p<0.05 was considered statistically significant.
Footnotes
Competing Interests: The authors have declared that no competing interests exist.
Funding: This work was supported by the Fundamental Research Funds for the Central Universities (No. 09YKPY76) and National Nature Science Foundation of China (No. 30872300). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
References
- 1.Shimokata K. Some problems concerning local cellular immunity in tuberculosis. Kekkaku. 1995;70:595–600. [PubMed] [Google Scholar]
- 2.Devergne O, Marfaing-Koka A, Schall TJ, Leger-Ravet MB, Sadick M, et al. Production of the RANTES chemokine in delayed-type hypersensitivity reactions: involvement of macrophages and endothelial cells. J Exp Med. 1994;179:1689–1694. doi: 10.1084/jem.179.5.1689. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Joshi R, Pai M. Can pleural tuberculosis be diagnosed using interferon-gamma release assays? Respiration. 2008;76:128–130. doi: 10.1159/000135933. [DOI] [PubMed] [Google Scholar]
- 4.Gopi A, Madhavan SM, Sharma SK, Sahn SA. Diagnosis and treatment of tuberculous pleural effusion in 2006. Chest. 2007;131:880–889. doi: 10.1378/chest.06-2063. [DOI] [PubMed] [Google Scholar]
- 5.Hoheisel G, Izbicki G, Roth M, Chan CH, Leung JC, et al. Compartmentalization of pro-inflammatory cytokines in tuberculous pleurisy. Respir Med. 1998;92:14–17. doi: 10.1016/s0954-6111(98)90025-7. [DOI] [PubMed] [Google Scholar]
- 6.Yamada Y, Nakamura A, Hosoda M, Kato T, Asano T, et al. Cytokines in pleural liquid for diagnosis of tuberculous pleurisy. Respir Med. 2001;95:577–581. doi: 10.1053/rmed.2001.1103. [DOI] [PubMed] [Google Scholar]
- 7.Light RW. Update on tuberculous pleural effusion. Respirology. 2010;15:451–458. doi: 10.1111/j.1440-1843.2010.01723.x. [DOI] [PubMed] [Google Scholar]
- 8.Sharma SK, Mitra DK, Balamurugan A, Pandey RM, Mehra NK. Cytokine polarization in miliary and pleural tuberculosis. J Clin Immunol. 2002;22:345–352. doi: 10.1023/a:1020604331886. [DOI] [PubMed] [Google Scholar]
- 9.Kaufmann SH, Cole ST, Mizrahi V, Rubin E, Nathan C. Mycobacterium tuberculosis and the host response. J Exp Med. 2005;201:1693–1697. doi: 10.1084/jem.20050842. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Mustafa AS. Development of new vaccines and diagnostic reagents against tuberculosis. Mol Immunol. 2002;39:113–119. doi: 10.1016/s0161-5890(02)00048-2. [DOI] [PubMed] [Google Scholar]
- 11.Soysal A, Millington KA, Bakir M, Dosanjh D, Aslan Y, et al. Effect of BCG vaccination on risk of mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet. 2005;366:1443–1451. doi: 10.1016/S0140-6736(05)67534-4. [DOI] [PubMed] [Google Scholar]
- 12.Young D, Dye C. The development and impact of tuberculosis vaccines. Cell. 2006;124:683–687. doi: 10.1016/j.cell.2006.02.013. [DOI] [PubMed] [Google Scholar]
- 13.Kaufmann SH. Recent findings in immunology give tuberculosis vaccines a new boost. Trends Immunol. 2005;26:660–667. doi: 10.1016/j.it.2005.09.012. [DOI] [PubMed] [Google Scholar]
- 14.Pathan AA, Wilkinson KA, Klenerman P, McShane H, Davidson RN, et al. Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD4 T cells in mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. J Immunol. 2001;167:5217–5225. doi: 10.4049/jimmunol.167.9.5217. [DOI] [PubMed] [Google Scholar]
- 15.Lalvani A, Nagvenkar P, Udwadia Z, Pathan AA, Wilkinson KA, et al. Enumeration of T cells specific for rd1-encoded antigens suggests a high prevalence of latent mycobacterium tuberculosis infection in healthy urban indians. J Infect Dis. 2001;183:469–477. doi: 10.1086/318081. [DOI] [PubMed] [Google Scholar]
- 16.Shams H, Klucar P, Weis SE, Lalvani A, Moonan PK, et al. Characterization of a mycobacterium tuberculosis peptide that is recognized by human CD4+ and CD8+ t cells in the context of multiple hla alleles. J Immunol. 2004;173:1966–1977. doi: 10.4049/jimmunol.173.3.1966. [DOI] [PubMed] [Google Scholar]
- 17.Ulrichs T, Munk ME, Mollenkopf H, Behr-Perst S, Colangeli R, et al. Differential T cell responses to mycobacterium tuberculosis ESAT6 in tuberculosis patients and healthy donors. Eur J Immunol. 1998;28:3949–3958. doi: 10.1002/(SICI)1521-4141(199812)28:12<3949::AID-IMMU3949>3.0.CO;2-4. [DOI] [PubMed] [Google Scholar]
- 18.Delgado JC, Baena A, Thim S, Goldfeld AE. Aspartic acid homozygosity at codon 57 of HLA-DQ beta is associated with susceptibility to pulmonary tuberculosis in cambodia. J Immunol. 2006;176:1090–1097. doi: 10.4049/jimmunol.176.2.1090. [DOI] [PubMed] [Google Scholar]
- 19.Mustafa AS, Shaban FA, Al-Attiyah R, Abal AT, El-Shamy AM, et al. Human Th1 cell lines recognize the mycobacterium tuberculosis ESAT-6 antigen and its peptides in association with frequently expressed HLA class II molecules. Scand J Immunol. 2003;57:125–134. doi: 10.1046/j.1365-3083.2003.01204.x. [DOI] [PubMed] [Google Scholar]
- 20.Raju B, Tung CF, Cheng D, Yousefzadeh N, Condos R, et al. In situ activation of helper T cells in the lung. Infect Immun. 2001;69:4790–4798. doi: 10.1128/IAI.69.8.4790-4798.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Santucci MB, Bocchino M, Garg SK, Marruchella A, Colizzi V, et al. Expansion of CCR5+ CD4+ T-lymphocytes in the course of active pulmonary tuberculosis. Eur Respir J. 2004;24:638–643. doi: 10.1183/09031936.04.000105403. [DOI] [PubMed] [Google Scholar]
- 22.Miki-Hosokawa T, Hasegawa A, Iwamura C, Shinoda K, Tofukuji S, et al. CD69 controls the pathogenesis of allergic airway inflammation. J Immunol. 2009;183:8203–8215. doi: 10.4049/jimmunol.0900646. [DOI] [PubMed] [Google Scholar]
- 23.Avgustin B, Kotnik V, Skoberne M, Malovrh T, Skralovnik-Stern A, et al. CD69 expression on CD4+ T lymphocytes after in vitro stimulation with tuberculin is an indicator of immune sensitization against Mycobacterium tuberculosis antigens. Clin Diagn Lab Immunol. 2005;12:101–106. doi: 10.1128/CDLI.12.1.101-106.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Hsieh SM, Hung CC, Pan SC, Wang JT, Tsai HC, et al. Restoration of cellular immunity against tuberculosis in patients coinfected with HIV-1 and tuberculosis with effective antiretroviral therapy: assessment by determination of CD69 expression on T cells after tuberculin stimulation. J Acquir Immune Defic Syndr. 2000;25:212–220. doi: 10.1097/00126334-200011010-00002. [DOI] [PubMed] [Google Scholar]
- 25.Udwadia ZF, Sen T. Pleural tuberculosis: an update. Curr Opin Pulm Med. 2010;16:399–406. doi: 10.1097/MCP.0b013e328339cf6e. [DOI] [PubMed] [Google Scholar]
- 26.Barnes PF, Lu S, Abrams JS, Wang E, Yamamura M, et al. Cytokine production at the site of disease in human tuberculosis. Infect Immun. 1993;61:3482–3489. doi: 10.1128/iai.61.8.3482-3489.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Jalapathy KV, Prabha C, Das SD. Correlates of protective immune response in tuberculous pleuritis. FEMS Immunol Med Microbiol. 2004;40:139–145. doi: 10.1016/S0928-8244(03)00303-1. [DOI] [PubMed] [Google Scholar]
- 28.Liang QL, Shi HZ, Wang K, Qin SM, Qin XJ. Diagnostic accuracy of adenosine deaminase in tuberculous pleurisy: a meta-analysis. Respir Med. 2008;102:744–754. doi: 10.1016/j.rmed.2007.12.007. [DOI] [PubMed] [Google Scholar]
- 29.Baba K, Hoosen AA, Langeland N, Dyrhol-Riise AM. Adenosine deaminase activity is a sensitive marker for the diagnosis of tuberculous pleuritis in patients with very low CD4 counts. PLoS One. 2008;3:e2788. doi: 10.1371/journal.pone.0002788. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Trajman A, Pai M, Dheda K, van Zyl Smit R, Zwerling AA, et al. Novel tests for diagnosing tuberculous pleural effusion: what works and what does not? Eur Respir J. 2008;31:1098–1106. doi: 10.1183/09031936.00147507. [DOI] [PubMed] [Google Scholar]
- 31.Hooper CE, Lee YC, Maskell NA. Interferon-gamma release assays for the diagnosis of TB pleural effusions: hype or real hope? Curr Opin Pulm Med. 2009;15:358–365. doi: 10.1097/MCP.0b013e32832bcc4e. [DOI] [PubMed] [Google Scholar]
- 32.Schierloh P, Yokobori N, Alemán M, Musella RM, Beigier-Bompadre M, et al. Increased susceptibility to apoptosis of CD56dimCD16+ NK cells induces the enrichment of IFN-gamma-producing CD56bright cells in tuberculous pleurisy. J Immunol. 2005;175:6852–6860. doi: 10.4049/jimmunol.175.10.6852. [DOI] [PubMed] [Google Scholar]
- 33.Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood. 2006;107:4781–4789. doi: 10.1182/blood-2005-12-4818. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Abel B, Tameris M, Mansoor N, Gelderbloem S, Hughes J, et al. The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults. Am J Respir Crit Care Med. 2010;181:1407–1417. doi: 10.1164/rccm.200910-1484OC. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Beveridge NE, Price DA, Casazza JP, Pathan AA, Sander CR, et al. Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur J Immunol. 2007;37:3089–3100. doi: 10.1002/eji.200737504. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Scriba TJ, Tameris M, Mansoor N, Smit E, van der Merwe L, et al. Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. Eur J Immunol. 2010;40:279–290. doi: 10.1002/eji.200939754. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Soares AP, Scriba TJ, Joseph S, Harbacheuski R, Murray RA, et al. Bacillus calmette-guerin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles. J Immunol. 2008;180:3569–3577. doi: 10.4049/jimmunol.180.5.3569. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Day CL, Mkhwanazi N, Reddy S, Mncube Z, van der Stok M, et al. Detection of polyfunctional Mycobacterium tuberculosis-specific T cells and association with viral load in HIV-1- infected persons. J Infect Dis. 2008;197:990–999. doi: 10.1086/529048. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Millington KA, Innes JA, Hackforth S, Hinks TS, Deeks JJ, et al. Dynamic relationship between IFNgamma and IL-2 profile of Mycobacterium tuberculosis-specific T cells and antigen load. J Immunol. 2007;178:5217–5226. doi: 10.4049/jimmunol.178.8.5217. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Caccamo N, Guggino G, Joosten SA, Gelsomino G, Di Carlo P, et al. Multifunctional CD4+ T cells correllate with active Mycobacterium tuberculosis infection. Eur J Immunol. 2010;40:2211–2220. doi: 10.1002/eji.201040455. [DOI] [PubMed] [Google Scholar]
- 41.Han Y, Guo Q, Zhang M, Chen Z, Cao X. CD69+ CD4+ CD25- T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-beta 1. J Immunol. 2009;182:111–120. doi: 10.4049/jimmunol.182.1.111. [DOI] [PubMed] [Google Scholar]
- 42.Guyot-Revol V, Innes JA, Hackforth S, Hinks T, Lalvani A. Regulatory T cells are expanded in blood and disease sites in patients with tuberculosis. Am J Respir Crit Care Med. 2006;173:803–810. doi: 10.1164/rccm.200508-1294OC. [DOI] [PubMed] [Google Scholar]
- 43.Li L, Lao SH, Wu CY. Increased frequency of CD4(+)CD25(high) Treg cells inhibit BCG-specific induction of IFN-gamma by CD4(+) T cells from TB patients. Tuberculosis. 2007;87:526–534. doi: 10.1016/j.tube.2007.07.004. [DOI] [PubMed] [Google Scholar]
- 44.Chen X, Zhou B, Li M, Deng Q, Wu X, et al. CD4(+)CD25(+)FoxP3(+) regulatory T cells suppress Mycobacterium tuberculosis immunity in patients with active disease. Clin Immunol. 2007;123:50–59. doi: 10.1016/j.clim.2006.11.009. [DOI] [PubMed] [Google Scholar]
- 45.Hougardy JM, Place S, Hildebrand M, Drowart A, Debrie AS, et al. Regulatory T cells depress immune responses to protective antigens in active tuberculosis. Am J Respir Crit Care Med. 2007;176:409–416. doi: 10.1164/rccm.200701-084OC. [DOI] [PubMed] [Google Scholar]
- 46.Sharma PK, Saha PK, Singh A, Sharma SK, Ghosh B, et al. FoxP3+ regulatory T cells suppress effector T-cell function at pathologic site in miliary tuberculosis. Am J Respir Crit Care Med. 2009;179:1061–1070. doi: 10.1164/rccm.200804-529OC. [DOI] [PubMed] [Google Scholar]
- 47.Ribeiro-Rodrigues R, Resende Co T, Rojas R, Toossi Z, Dietze R, et al. A role for CD4+CD25+ T cells in regulation of the immune response during human tuberculosis. Clin Exp Immunol. 2006;144:25–34. doi: 10.1111/j.1365-2249.2006.03027.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Li L, Wu CY. CD4+ CD25+ Treg cells inhibit human memory gammadelta T cells to produce IFN-gamma in response to M tuberculosis antigen ESAT-6. Blood. 2008;111:5629–5636. doi: 10.1182/blood-2008-02-139899. [DOI] [PubMed] [Google Scholar]